GeoVax Labs Receives Nasdaq Delisting Determination

What Happened

• On August 27, 2026, GeoVax Labs, Inc. (GOVX) received a Staff Determination Letter from Nasdaq notifying the company that Nasdaq has determined to delist its common stock.
• Nasdaq found GeoVax’s closing bid price was below the $1.00 minimum for continued listing for 30 consecutive business days from July 16, 2026 through August 26, 2026, in violation of Nasdaq Listing Rule 5550(a)(2).
• Because GeoVax effected a 1-for-25 reverse stock split on January 12, 2026, it is not eligible for the usual 180-calendar-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv). The company also previously received notice of noncompliance with the $2,500,000 stockholders’ equity requirement under Nasdaq Listing Rule 5550(b).
• Absent a timely hearing request, Nasdaq expects trading in the Company’s securities to be suspended at the opening of business on September 8, 2026. GeoVax plans to request a hearing by the September 3, 2026 deadline; a timely request will stay further action and the shares will continue trading on Nasdaq during the appeal.

Key Details

• Date of determination: August 27, 2026.
• Minimum bid-price violation period: July 16, 2026 – August 26, 2026 (30 consecutive business days).
• Reverse split: 1-for-25 on January 12, 2026 (affects eligibility for cure period).
• Suspension expected (if no appeal): opening of business on September 8, 2026; hearing request deadline: September 3, 2026.

Why It Matters

• A delisting determination is material because delisting or suspension can reduce liquidity, limit investor access, and may result in the stock moving to over-the-counter markets if Nasdaq listing is lost.
• GeoVax’s timely appeal will keep the stock trading on Nasdaq during the review, but there is no guarantee the Hearings Panel will reverse the determination or that the company will regain compliance with Nasdaq listing standards. Investors should monitor the hearing outcome and any company announcements about plans to cure the deficiencies.